Antimicrobial Compounds for Killing Persister and VBNC Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against persister cells and dormant 'viable but non-culturable' (VBNC) cells, leading to recalcitrant bacterial infections.
Innovation Solution
Compounds such as [(5-nitro-3-phenyl-1H-indol-2-yl)methyl]amine hydrochloride (NPIMA) and 2-{[2-(4-bromophenyl)-2-oxoethyl]thio}-3-ethyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one (BPOET) are used to kill or reduce persister cells and VBNC cells in bacterial populations, including pathogenic bacteria like Escherichia spp., Staphylococcus spp., and Pseudomonas spp.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then actively growing bacteria are killed, but persister cells and VBNC cells survive and reconstitute infections
Solution Approach 1:
The patent changes the chemical parameters of antimicrobial compounds by developing novel structures (such as compound 1 with specific molecular architecture) that differ from traditional antibiotics. These structural parameter changes enable the compounds to kill persister cells while maintaining effectiveness against actively growing bacteria, thereby resolving the contradiction between killing growing bacteria and eliminating persisters.
Solution Approach 2:
The patent creates composite antimicrobial solutions by combining novel compound structures with specific pharmacological properties. The composite nature of these compounds—integrating multiple functional groups and molecular features—enables them to overcome persister cell tolerance mechanisms that traditional single-function antibiotics cannot penetrate, thus improving treatment reliability against all bacterial states.
2Reliability
If new antibiotics are discovered to kill persister cells, then treatment effectiveness improves, but the complexity of drug development increases
Solution Approach 1:
The patent segments the antibiotic development process by focusing on specific molecular architectures and key structural features that confer persister cell killing activity. Rather than conducting exhaustive searches across all possible compounds, the invention identifies and optimizes particular structural segments and molecular patterns, thereby reducing development complexity while maintaining high effectiveness against persisters.
Solution Approach 2:
The novel antibiotic compounds described in the patent possess multi-functional properties: they can kill actively growing bacteria, eradicate persister cells, and maintain stability under various conditions. This universality means a single compound class can address multiple aspects of bacterial infections simultaneously, reducing the need for multiple different drugs and simplifying treatment protocols despite the complexity of discovering such multi-functional agents.
Data Source
AI summary
Disclosed herein are compounds, compositions, and methods for treating infections by bacteria and for killing bacteria. In particular, the disclosed compounds, compositions, and methods are useful for treating infections by bacteria and for killing persister bacteria that survive antibiotic treatment and then reconstitute infections.